Ciprofloxacin as a therapeutic modality in pediatric burn wound infections

Efficacious or contraindicated?

John P. Heggers, Cynthia Villarreal, Pat Edgar, Steven Wolf, Gordon L. Klein, Susan D. John, Manu Desai, David N. Herndon

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies. For this reason, such therapy is contraindicated in the pediatric population. However, several studies in children with cystic fibrosis have found the drug to be efficacious. Our hypothesis was that ciprofloxacin treatment is justified in the case of multiresistant organisms in burn populations. Design: During a 4- year period (January 1, 1993, to December 31, 1997) we treated 56 of our pediatric burn patients with ciprofloxacin when cultures proved resistant to other antibiotics. The burn area was 65% of the total body surface area. The average patient age was 8.4 years. Of the 56 patients who received ciprofloxacin, 50 received the recommended dose. Biopsy specimens were assessed for quantitative bacteriology and antibiotic sensitivity. Radiologic review was conducted to examine for arthropathy. Results: All patients showed unequivocal reduction in quantitative bacterial counts, and susceptibility to ciprofloxacin remained stable without the development of resistance. Of the 56 patients treated, 42 had a major reduction in their quantitative wound biopsies from 106 to less than 100 colonies per gram of tissue, while the remaining 14 were observed to have a 2- to 3-log decrease. No arthropathy was detected in any of the 56 patients receiving ciprofloxacin. Review of the patients' charts showed no documented adverse events associated with the use of ciprofloxacin. All patients survived their thermal injury and the complications associated with it without any untoward problems or complications of arthropathy. Conclusion: On the basis of these data, ciprofloxacin therapy in the treatment of immunosuppressed pediatric burn patients is efficacious and does not cause arthropathy.

Original languageEnglish (US)
Pages (from-to)1247-1250
Number of pages4
JournalArchives of Surgery
Volume133
Issue number11
StatePublished - Nov 1998

Fingerprint

Wound Infection
Ciprofloxacin
Pediatrics
Joint Diseases
Therapeutics
Anti-Bacterial Agents
Biopsy
Bacteriology
Bacterial Load
Drug and Narcotic Control
Body Surface Area
Wounds and Injuries
United States Food and Drug Administration
Cystic Fibrosis
Population
Hot Temperature

ASJC Scopus subject areas

  • Surgery

Cite this

Heggers, J. P., Villarreal, C., Edgar, P., Wolf, S., Klein, G. L., John, S. D., ... Herndon, D. N. (1998). Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: Efficacious or contraindicated? Archives of Surgery, 133(11), 1247-1250.

Ciprofloxacin as a therapeutic modality in pediatric burn wound infections : Efficacious or contraindicated? / Heggers, John P.; Villarreal, Cynthia; Edgar, Pat; Wolf, Steven; Klein, Gordon L.; John, Susan D.; Desai, Manu; Herndon, David N.

In: Archives of Surgery, Vol. 133, No. 11, 11.1998, p. 1247-1250.

Research output: Contribution to journalArticle

Heggers, JP, Villarreal, C, Edgar, P, Wolf, S, Klein, GL, John, SD, Desai, M & Herndon, DN 1998, 'Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: Efficacious or contraindicated?', Archives of Surgery, vol. 133, no. 11, pp. 1247-1250.
Heggers JP, Villarreal C, Edgar P, Wolf S, Klein GL, John SD et al. Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: Efficacious or contraindicated? Archives of Surgery. 1998 Nov;133(11):1247-1250.
Heggers, John P. ; Villarreal, Cynthia ; Edgar, Pat ; Wolf, Steven ; Klein, Gordon L. ; John, Susan D. ; Desai, Manu ; Herndon, David N. / Ciprofloxacin as a therapeutic modality in pediatric burn wound infections : Efficacious or contraindicated?. In: Archives of Surgery. 1998 ; Vol. 133, No. 11. pp. 1247-1250.
@article{d4b1dc6ad0334d39b296d4b5387cb209,
title = "Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: Efficacious or contraindicated?",
abstract = "Background: Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies. For this reason, such therapy is contraindicated in the pediatric population. However, several studies in children with cystic fibrosis have found the drug to be efficacious. Our hypothesis was that ciprofloxacin treatment is justified in the case of multiresistant organisms in burn populations. Design: During a 4- year period (January 1, 1993, to December 31, 1997) we treated 56 of our pediatric burn patients with ciprofloxacin when cultures proved resistant to other antibiotics. The burn area was 65{\%} of the total body surface area. The average patient age was 8.4 years. Of the 56 patients who received ciprofloxacin, 50 received the recommended dose. Biopsy specimens were assessed for quantitative bacteriology and antibiotic sensitivity. Radiologic review was conducted to examine for arthropathy. Results: All patients showed unequivocal reduction in quantitative bacterial counts, and susceptibility to ciprofloxacin remained stable without the development of resistance. Of the 56 patients treated, 42 had a major reduction in their quantitative wound biopsies from 106 to less than 100 colonies per gram of tissue, while the remaining 14 were observed to have a 2- to 3-log decrease. No arthropathy was detected in any of the 56 patients receiving ciprofloxacin. Review of the patients' charts showed no documented adverse events associated with the use of ciprofloxacin. All patients survived their thermal injury and the complications associated with it without any untoward problems or complications of arthropathy. Conclusion: On the basis of these data, ciprofloxacin therapy in the treatment of immunosuppressed pediatric burn patients is efficacious and does not cause arthropathy.",
author = "Heggers, {John P.} and Cynthia Villarreal and Pat Edgar and Steven Wolf and Klein, {Gordon L.} and John, {Susan D.} and Manu Desai and Herndon, {David N.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "133",
pages = "1247--1250",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Ciprofloxacin as a therapeutic modality in pediatric burn wound infections

T2 - Efficacious or contraindicated?

AU - Heggers, John P.

AU - Villarreal, Cynthia

AU - Edgar, Pat

AU - Wolf, Steven

AU - Klein, Gordon L.

AU - John, Susan D.

AU - Desai, Manu

AU - Herndon, David N.

PY - 1998/11

Y1 - 1998/11

N2 - Background: Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies. For this reason, such therapy is contraindicated in the pediatric population. However, several studies in children with cystic fibrosis have found the drug to be efficacious. Our hypothesis was that ciprofloxacin treatment is justified in the case of multiresistant organisms in burn populations. Design: During a 4- year period (January 1, 1993, to December 31, 1997) we treated 56 of our pediatric burn patients with ciprofloxacin when cultures proved resistant to other antibiotics. The burn area was 65% of the total body surface area. The average patient age was 8.4 years. Of the 56 patients who received ciprofloxacin, 50 received the recommended dose. Biopsy specimens were assessed for quantitative bacteriology and antibiotic sensitivity. Radiologic review was conducted to examine for arthropathy. Results: All patients showed unequivocal reduction in quantitative bacterial counts, and susceptibility to ciprofloxacin remained stable without the development of resistance. Of the 56 patients treated, 42 had a major reduction in their quantitative wound biopsies from 106 to less than 100 colonies per gram of tissue, while the remaining 14 were observed to have a 2- to 3-log decrease. No arthropathy was detected in any of the 56 patients receiving ciprofloxacin. Review of the patients' charts showed no documented adverse events associated with the use of ciprofloxacin. All patients survived their thermal injury and the complications associated with it without any untoward problems or complications of arthropathy. Conclusion: On the basis of these data, ciprofloxacin therapy in the treatment of immunosuppressed pediatric burn patients is efficacious and does not cause arthropathy.

AB - Background: Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies. For this reason, such therapy is contraindicated in the pediatric population. However, several studies in children with cystic fibrosis have found the drug to be efficacious. Our hypothesis was that ciprofloxacin treatment is justified in the case of multiresistant organisms in burn populations. Design: During a 4- year period (January 1, 1993, to December 31, 1997) we treated 56 of our pediatric burn patients with ciprofloxacin when cultures proved resistant to other antibiotics. The burn area was 65% of the total body surface area. The average patient age was 8.4 years. Of the 56 patients who received ciprofloxacin, 50 received the recommended dose. Biopsy specimens were assessed for quantitative bacteriology and antibiotic sensitivity. Radiologic review was conducted to examine for arthropathy. Results: All patients showed unequivocal reduction in quantitative bacterial counts, and susceptibility to ciprofloxacin remained stable without the development of resistance. Of the 56 patients treated, 42 had a major reduction in their quantitative wound biopsies from 106 to less than 100 colonies per gram of tissue, while the remaining 14 were observed to have a 2- to 3-log decrease. No arthropathy was detected in any of the 56 patients receiving ciprofloxacin. Review of the patients' charts showed no documented adverse events associated with the use of ciprofloxacin. All patients survived their thermal injury and the complications associated with it without any untoward problems or complications of arthropathy. Conclusion: On the basis of these data, ciprofloxacin therapy in the treatment of immunosuppressed pediatric burn patients is efficacious and does not cause arthropathy.

UR - http://www.scopus.com/inward/record.url?scp=0031738389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031738389&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 1247

EP - 1250

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 11

ER -